Description
Generic Drug of Bortezomib Available in India?
Bortezomib is the generic name of the medication and is its international nonproprietary name. Bortezomib is marketed under the brand name Borteplus among others. Bortezomib Injection, a proteasome inhibitor, contains bortezomib, which is an antineoplastic agent. This NDA provides for the use of Bortezomib Injection for the treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.
Bortezomib, a first in class protease inhibitor (PI) was approved in 2003 for the treatment of progressive MM in patients who had received at least two prior therapies. In combination with melphalan and prednisone, it is also indicated for the treatment of adult patients with previously untreated MM who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Currently, it has been recommended for primary induction therapy and also for consolidation and salvage therapy post relapse.
Since its development, bortezomib has come a long way in treating MM patients. Its wider therapeutic spectrum ranging from frontline induction to maintenance therapy has been increasingly explored in studies with the goal of achieving deeper responses, longer progression free survival (PFS), and possibly overall survival (OS). Bortezomib, in combination with other drugs, can also be reused in relapse setting.
Novel drugs, such as carfilzomib, Ixazomib, and pomalidomide, have also been introduced lately, leading to the bright future of MM patients.
Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004. It is on the World Health Organization’s List of Essential Medicines. It is available as a generic medication.
Will this product be accessible across all regions of India?
The product – Borteplus (Bortezomib) Injection will be available across India on request. Bortezomib is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune. To get or place an order from Aark Pharmaceuticals, a pharma distributor in India, please call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
List of available brand-name drugs in India for Bortezomib Injection.
Indian pharmaceutical company has received approval from the US Food and Drug Administration (USFDA) for its product, ‘Bortezomib Injection NDA 212782’.
List of Generic version of Bortezomib for injection available with Aark: Bortether, Proteoz, Myzomib, Myezom, Mibor, Borviz, Bortrac, Bortirel, Borteshil, Borteplus, Bortenat , Bortemap, Borte Trust.
NEWS / UPDATES
- Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine.
- GSK blood cancer drug nearly halves risk of death in late-stage trial.
- Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market.
- Aurobindo Pharma gets USFDA nod for generic cancer drug Bortezomib.
- Zydus receives final approval from USFDA for Bortezomib for Injection.
